Search results (123)
« Back to NewsNucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
21 October 2024
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.
Internationally renowned academic Lee Sweetlove joins Moa
15 October 2024
Moa Technology is pleased to announce that Lee Sweetlove, Professor of Plant Sciences at the University of Oxford, has joined our team. Professor Sweetlove will be working to further understanding of the novel herbicidal modes of action discovered by Moa, which we are currently developing into safe, effective and affordable solutions to protect harvests from crop-killing weeds.
Moa’s groundbreaking science features in journal Weed Science
9 October 2024
Breaking the 30 year impasse in novel herbicide discovery.
Enara Bio raises $32.5M Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®
2 October 2024
Enara Bio today announces the closing of a $32.5M Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventures and M Ventures, with participation from all existing investors, including RA Capital, Samsara BioCapital and SV Health Investors.
OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2
30 September 2024
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the candidate nomination of its lead program targeting the melanocortin-2 (MC2) receptor and key appointments to support its progress towards becoming a clinical-stage company.
Moa and Biomar announce bio-herbicide collaboration
16 September 2024
Moa has boosted its bio-herbicide research and development programme with a new long-term collaboration agreement with Biomar Microbial Technologies.
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
11 September 2024
Alchemab Therapeutics (Alchemab), a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Chief Scientific Officer (CSO), has succeeded Young Kwon, PhD as Chief Executive Officer (CEO) and member of the Board.
CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases
9 September 2024
CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has secured $6.5M in seed funding led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures.
Moa announces international field trial success at the ACS autumn conference in Denver
19 August 2024
Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.
CyanoCapture continues to make strides in the green sciences industry
11 August 2024
CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Oréal organised in collaboration with Genopole and Hello Tomorrow.
Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer
15 July 2024
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.
Moa harvests global deal for new herbicide
7 July 2024
Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.
GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease
11 June 2024
Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
5 June 2024
Former BioEscalator tenant Alchemab Therapeutics continues to make significant strides in Parkinson's disease research, recently receiving a substantial grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its innovative antibody discovery program.
CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery
17 April 2024
The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.
Ochre Bio outgrows the BioEscalator
27 October 2022
With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.
The BioEscalator bids farewell to Nucleome Therapeutics
26 September 2022
Nucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.
PepGen graduates from the BioEscalator
31 July 2022
PepGen is the last of the original cohort of companies that moved into the BioEscalator when it first opened. The new PepGen headquarters in Boston, USA, will manage late-stage preclinical testing and clinical and regulatory functions.
Introducing Theraport
30 June 2022
Winner of OUBT's Biohackathon 2022, part of the Oxford Catalyse Programme, Theraport join the BioEscalator community for three months.
CyanoCapture moves on from the BioEscalator
15 May 2022
The company has moved into the newly refurbished Hayakawa Building at the Oxford Science Park.